Polycystic ovary syndrome has been renamed polyendocrine metabolic ovarian syndrome, or PMOS, by an international consortium of researchers [1, 2].
The change aims to remove a misleading title and better describe how the condition affects reproductive, hormonal, and metabolic health. Experts said the new terminology will help improve diagnosis and patient care [1, 2, 5].
The decision follows 14 years of research [1]. This effort included the collection of 22,000 survey responses to understand the impact of the syndrome [1]. The name change was publicly reported in early 2026 [3].
Medical professionals said that the previous name focused too heavily on ovarian cysts, which are not present in every patient. By shifting the focus to the endocrine and metabolic components, the new name captures the broader systemic nature of the disorder [1, 2].
Estimates of the condition's prevalence vary. Some reports state that 170 million women worldwide are affected [4], while others describe the impact as reaching tens of millions of women [6].
While the condition is primarily described as a women's health issue [2], some reports indicate that men may also have a version of the syndrome [3]. The international consortium said the update is necessary to ensure that the medical community treats the condition as a complex metabolic disorder rather than a localized reproductive issue [1, 2].
“The name change was announced to better reflect its endocrine and metabolic components.”
This shift in terminology represents a move toward precision medicine. By removing the emphasis on 'polycystic ovaries' — a feature not universal to all patients — the medical community is redefining the disorder by its systemic metabolic drivers. This could lead to more accurate screenings and a broader approach to treatment that prioritizes hormonal and metabolic stability over the mere presence of ovarian cysts.
